Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

GUEST COMMENTARY—For millions of patients, the slow pace of drug discovery means years – sometimes decades – without effective treatments. Many diseases remain untreatable, not because they are rare ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...